BTIG Research Issues Pessimistic Forecast for Intuitive Surgical (NASDAQ:ISRG) Stock Price

Intuitive Surgical (NASDAQ:ISRG) had its price target decreased by investment analysts at BTIG Research from $469.00 to $454.00 in a research report issued on Monday, Marketbeat.com reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. BTIG Research’s price objective suggests a potential upside of 7.57% from the stock’s previous close.

A number of other equities research analysts have also weighed in on ISRG. Wall Street Zen lowered shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Sunday, September 20th. KeyCorp reiterated an “overweight” rating on shares of Intuitive Surgical in a research note on Wednesday, August 12th. Evercore set a $430.00 price objective on Intuitive Surgical in a report on Monday, July 6th. BNP Paribas Exane raised Intuitive Surgical to an “outperform” rating in a report on Tuesday, July 28th. Finally, Citigroup lowered their price objective on Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $498.83.

Intuitive Surgical Trading Down 1.3%

ISRG opened at $422.06 on Monday. The company’s fifty day moving average price is $388.49 and its two-hundred day moving average price is $410.14. Intuitive Surgical has a 1-year low of $328.57 and a 1-year high of $603.88. The company has a market cap of $149.11 billion, a price-to-earnings ratio of 51.21, a PEG ratio of 3.23 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.48 by $0.32. The firm had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The business’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same period last year, the firm earned $1.81 earnings per share. As a group, equities analysts forecast that Intuitive Surgical will post 8.87 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $379.00, for a total transaction of $151,600.00. Following the transaction, the executive vice president owned 5,320 shares of the company’s stock, valued at $2,016,280. This trade represents a 6.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 72 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $393.10, for a total value of $28,303.20. Following the completion of the transaction, the director owned 179 shares in the company, valued at $70,364.90. The trade was a 28.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 12,370 shares of company stock worth $4,891,989 in the last ninety days. 0.60% of the stock is owned by corporate insiders.

Institutional Trading of Intuitive Surgical

A number of institutional investors and hedge funds have recently modified their holdings of ISRG. Salem Investment Counselors Inc. lifted its holdings in Intuitive Surgical by 1.2% during the third quarter. Salem Investment Counselors Inc. now owns 64,200 shares of the medical equipment provider’s stock worth $26,106,000 after acquiring an additional 761 shares during the period. Signal Advisors Wealth LLC grew its stake in Intuitive Surgical by 9.4% in the 3rd quarter. Signal Advisors Wealth LLC now owns 11,385 shares of the medical equipment provider’s stock valued at $4,629,000 after purchasing an additional 981 shares during the period. B. Riley Wealth Advisors Inc. grew its stake in Intuitive Surgical by 28.7% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 7,875 shares of the medical equipment provider’s stock valued at $3,202,000 after purchasing an additional 1,754 shares during the period. Krilogy Financial LLC grew its stake in Intuitive Surgical by 79.9% in the 3rd quarter. Krilogy Financial LLC now owns 12,467 shares of the medical equipment provider’s stock valued at $5,331,000 after purchasing an additional 5,538 shares during the period. Finally, Lineweaver Wealth Advisors LLC grew its stake in Intuitive Surgical by 15.4% in the 3rd quarter. Lineweaver Wealth Advisors LLC now owns 1,846 shares of the medical equipment provider’s stock valued at $751,000 after purchasing an additional 246 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive Surgical is expanding beyond traditional surgery by submitting a next-generation robotic endoscope to the FDA for gastrointestinal procedures. Approval could open a significant new growth market and broaden the company’s recurring-procedure opportunity. ISRG Is Expanding Beyond Surgery: Here’s Why the GI Opportunity Matters
• Positive Sentiment: Zacks upgraded ISRG to Rank #2, or “Buy,” citing improving earnings prospects. The upgrade may support sentiment ahead of the company’s quarterly report. Intuitive Surgical Upgraded to Buy
• Positive Sentiment: UBS reiterated a Buy rating and maintained a $500 price target, pointing to Intuitive Surgical’s long-term robotic-surgery growth runway. Leerink Partners also maintained its Buy recommendation. Intuitive Surgical Buy Rating Reiterated
• Positive Sentiment: Erste Group raised its fiscal 2027 EPS estimate slightly to $10.09 from $10.06, above the current-year consensus estimate of $8.87, reinforcing expectations for continued earnings growth.
• Neutral Sentiment: Intuitive Surgical is being highlighted as a sales-growth stock ahead of third-quarter earnings. Its prior quarter included 18.4% year-over-year revenue growth and an earnings beat, but investors are likely waiting for updated results and guidance. 3 Sales Growth Stocks to Buy as Q3 Earnings Get Underway
• Negative Sentiment: BTIG lowered its price target to $454 from $469 while keeping a Buy rating. Although the revised target still implies upside, the cut may weigh on near-term sentiment and signals more cautious expectations.
• Negative Sentiment: Valuation remains a potential pressure point: Intuitive Surgical trades at a substantially higher forward earnings multiple than Abbott Laboratories, leaving the stock sensitive to any earnings miss, slower procedure growth, or conservative guidance. Abbott Laboratories vs. Intuitive Surgical

About Intuitive Surgical

Intuitive Surgical, Inc develops and commercializes robotic-assisted systems and related technologies designed to support minimally invasive medical procedures. The company’s products are intended to help surgeons perform operations through small incisions while providing enhanced visualization, precision, and control.

Its principal product is the da Vinci Surgical System, a platform used across a range of specialties, including general surgery, urology, gynecology, thoracic surgery, and cardiac procedures.